PPAR-γ activation inhibits EP3 expression by inhibiting NF-κB activity.

<p>(A-a) Immunocytochemical analysis of nuclear NF-κB expression in THP-1 macrophages treated with the PPAR-γ agonist, troglitazone (10 µM), for 24 h. Scale bar = 50 µm. (A-b) Statistical analysis of the number of nuclear NF-κB-positive cells based on the immunocytochemical results. (B) Real-time PCR analysis of EP3 mRNA expression following addition of parthenolide (5 µM) for 24 h. (C) Western blot analysis of EP3 protein expression with parthenolide (5 µM) for 24 h. (D) Real-time PCR analysis of the ChIP assay examining the binding of NF-κB to EP3 in THP-1 macrophages treated with troglitazone (10 µM) for 24 h. Data are from 3 experiments<b>.</b> * P<0.05 versus control.